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A number of nucleotide and non-nucleoside inhibitors of HCV polymerase are currently under investigation as potential antiviral agents
to treat HCV-infected patients. HCV polymerase is part of a replicase complex including the polymerase subunit NS5B together with other
viral and host proteins and viral RNA. The RNA synthesis activity of the native replicase complex was inhibited by 3V-deoxy-CTP, a chain-
terminating nucleotide analog, but not inhibited by non-nucleoside NS5B polymerase inhibitors of three different structural classes. The HCV
replicase was also resistant to heparin, a broad-spectrum, RNA-competitive polymerase inhibitor. Prebinding of the recombinant NS5B
protein with a RNA template rendered the polymerase largely resistant to the inhibition by heparin and the non-nucleoside inhibitors, but did
not affect the inhibitory potency of 3V-deoxy-CTP. Therefore, the HCV replicase showed a similar pattern of inhibitor sensitivity as compared
to RNA-bound NS5B. These results suggest that the native HCV replicase complex represents a stable and productive polymerase–RNA
complex. The allosteric non-nucleoside NS5B polymerase inhibitors are inactive against established HCV replicase but may function
antagonistically with the formation of a productive enzyme–template complex.
D 2004 Elsevier Inc. All rights reserved.
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RNA replication of hepatitis C virus (HCV) occurs in
cytoplasm and is mediated by a membrane-associated
replicase complex consisting of many if not all of the NS
proteins and possibly host factor(s) (Moradpour et al.,
2003). NS5B, the RNA-dependent RNA polymerase
(RdRp), is the catalytic subunit of the replicase complex
and therefore constitutes a prime target for anti-viral
intervention. Using recombinant NS5B protein for screen-
ing, both nucleotide and non-nucleoside inhibitors of0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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klaus.klumpp@roche.com (K. Klumpp).HCV polymerase activity have been identified. Nucleotide
analogs target the polymerase active site, are mostly
competitive inhibitors relative to the natural nucleotide
substrates, and can cause chain termination upon incor-
poration into the RNA molecules (Carroll et al., 2003;
Migliaccio et al., 2003; Shim et al., 2003). Non-nucleo-
side inhibitors of NS5B RNA synthesis activity have been
independently identified by several laboratories and
belong to a number of different structural classes
(Beaulieu et al., 2004; Chan et al., 2004a, 2004b; Dhanak
et al., 2002; McKercher et al., 2004). Based on the
location of resistance conferring amino acids on NS5B,
cross-resistance studies and co-crystal structure informa-
tion, benzimidazole, benzothiadiazine, and thiophene
carboxylic-acid-based compounds bind to three non-over-
lapping binding sites on NS5B (Love et al., 2003;
Nguyen et al., 2003; Tomei et al., 2003, 2004; Wang et005) 8–15
Rapid Communication 9al., 2003). Benzothiadiazine and benzimidazole inhibitors
did not inhibit NS5B activity under single-cycle RNA
synthesis conditions (Gu et al., 2003; McKercher et al.,
2004). Therefore, the potency of these non-nucleoside
inhibitors may be dependent on the status of the enzyme–
template interaction, and HCV polymerase inhibition may
only be occurring during the initiation phase of RNA
synthesis. Despite the widespread use of recombinant
NS5B as an in vitro model of HCV-specific RNA
synthesis, the impact of NS5B interaction with other
HCV replicase subunits on the inhibitory potency of
polymerase inhibitors remains unclear. The HCV replicon
system in hepatoma cells provides a source of native
replicase complex, which could be used to address this
issue, independent of potential differences in cell pene-
tration or cellular toxicity between investigational com-
pounds. Here, the inhibition of HCV replicase activity
was determined using representative examples of non-
nucleoside inhibitors of three different structural classes
and a nucleotide analog.Fig. 1. Isolated CRC contains multiple HCV NS proteins and is enzymatically activ
residing protein GRP78 in the membrane fraction from Huh7 (H) or replicon
polyclonal antisera against NS5B, NS5A, and NS3 were developed using recomb
antibody against NS4B (4B52) was kindly provided by Dr. Kohara (Tsukiyama-K
cytoplasmic membrane fractions. Membrane fraction from Huh7 (H) or replicon (R
each of ATP, UTP, and GTP (AUG). M, radiolabeled single-strand replicon RNA. (
of replicase assay in which 10 Al of CRC was included in the reactions for indica
lower panel. R2 values represent the goodness of linear regression of the data.Results
Biological characterization of membrane-associated
replicase complex
HCV polymerase NS5B is a membrane-associated
protein and part of a multiprotein replicase complex
(Moradpour et al., 2003). A cell-free preparation of
enzymatically active HCV replicase complex was isolated
as a cytoplasmic membrane fraction from Huh-7 cells
harboring a subgenomic NS3-5B replicon (Krieger et al.,
2001) by Dounce homogenizing and differential centrifu-
gation (Takeda et al., 1986). The HCV protein composition
of the cytoplasmic replicase complex (CRC) obtained by
this method was determined by Western blotting analysis.
NS3, NS4B, NS5A, and NS5B were present in the CRC
fraction from replicon cells, but not in the corresponding
membrane fraction from parent, replicon-free Huh-7 cells
(Fig. 1A). As a control, GRP78, a chaperone protein
residing in endoplasmic reticulum (ER), was confirmed toe. (A) Detection of HCV nonstructural proteins and endoplasmic reticulum-
(R) cells. Molecular weights of proteins are indicated on the left. Rabbit
inant NS5B, NS5A, or NS3 protease domain as immunogens. Monoclonal
ohara et al., 2004). (B) NTP-dependent in vitro RNA synthesis activity of
) cells was incubated with [a-33P]-CTP in the presence or absence of 1 mM
C) Enzyme-dependent RNA synthesis activity of replicase. (D) Time course
ted time points. RNA bands were quantitated and plotted as shown on the
Fig. 2. Effect of nucleotide and non-nucleoside inhibitors on replicase
activity. (A) Structures of inhibitor compounds. (B) Inhibition of replicase
activity by nucleotide and non-nucleoside inhibitors. Replicase activity was
determined in the presence of nucleotide analog 3V-dCTP at concentrations
of 0.01, 0.03, 0.09, 0.28, 0.83, 2.5, and 7.5 AM, or each of the non-
nucleoside inhibitors at concentrations of 0.032, 0.16, 0.8, 4, 20, and 100
AM. C, replicase activity in the absence of inhibitor; 3dC, replicase activity
in the presence of 7.5 AM 3V-dCTP.
Rapid Communication10be present both in the membrane fractions from parent Huh-
7 cells as well as Huh-7-derived cells containing HCV
replicon (Fig. 1A). In the presence of exogenous nucleotide
triphosphates (NTPs), the replicase complex was able to
synthesize full-length copies of the endogenous replicon
RNA template (Fig. 1B). The major product of RNA
synthesis by CRC was full-length replicon RNA. The RNA
product was not seen with the corresponding membrane
fraction from Huh-7 parent cells or when only a single NTP
was provided (Fig. 1B). Therefore, the synthesis of HCV
replicon RNA in vitro was HCV-replicase-specific and
NTP-dependent. The replicase-associated RNA synthesis
activity was dependent on the amount of protein complex in
the reaction. A linear increase of product formation was
observed up to 12.5 Al CRC, where 1 Al of CRC represented
membrane fraction from 5  105 cells (Fig. 1C). In the
presence of 10 Al CRC, full-length RNA synthesis also
increased linearly with time up to 180 min (Fig. 1D).
Similar results were obtained with multiple CRC prepara-
tions suggesting highly robust and reproducible HCV
replicase activity obtained by using the current cell
fractionation protocol. Ten-microliter CRC and an incuba-
tion time of 120 min were established as standard replicase
assay conditions for inhibitor characterization. According to
comparative Western blot analysis using recombinant NS5B
as a reference, the NS5B concentration in the standard
replicase assay was similar within 2-fold to that used in the
standard recombinant NS5B polymerase assay (data not
shown).
Inhibition of replicase activity by nucleotide analog and
non-nucleoside inhibitors
A number of HCV polymerase inhibitors have been
identified using recombinant NS5B proteins in isolation
from other replicase subunits in vitro. Different compounds
were selected to compare inhibitory potencies using in vitro
RNA synthesis assays with HCV replicase (CRC) or
recombinant HCV polymerase (NS5B570-BK). The inhib-
itors tested include a chain-terminating nucleotide analog,
3V-deoxycytidine triphosphate (3V-dCTP), and a representa-
tive molecule from each of three different classes of non-
nucleoside inhibitors: compound 1 based on a benzimida-
zole scaffold (Beaulieu et al., 2004; Dhanak et al., 2002),
compound 2 based on a benzothiadiazine structure (Dhanak
et al., 2002), and compound 3 based on a thiophene
carboxylic acid scaffold (Chan et al., 2004a, 2004b) (Fig.
2A). Based on structural and mutational analysis, these four
compounds bind to distinct binding sites on NS5B. 3V-
dCTP significantly inhibited the RNA synthesis activity of
the HCV replicase, with complete inhibition achieved at 7.5
AM (Fig. 2B). Surprisingly, none of the non-nucleoside
inhibitors showed an inhibitory effect on HCV replicase
activity at concentrations up to 100 AM, despite full
inhibition of replicase by 7.5 AM 3V-dCTP in control
reactions (Fig. 2B). 3V-dCTP inhibited RNA synthesisactivity of recombinant NS5B and the replicase complex
with similar potency (Table 1). All three non-nucleoside
inhibitors tested inhibited the RNA synthesis activity of
NS5B570-BK on a heteropolymeric RNA template derived
from the 3V-end of the negative-strand HCV genome
(cIRES) with submicromolar IC50 values, similar to
previously published values (Table 1). The RNA synthesis
activity of NS5B was inhibited to more than 90%
completion by each of the three non-nucleoside inhibitors
at 100 AM (data not shown), a concentration at which
replicase activity was not inhibited.
Replicase activity is resistant to heparin inhibition
The different sensitivity of the recombinant RdRp and
the replicase to the inhibition of allosteric non-nucleoside
inhibitors suggested that the RdRp in the replicase complex
may assume a different conformation due to its interaction
with the endogenous HCV RNA template, other viral
proteins, or host cofactors. Sensitivity of the RdRp activity
to heparin was used to test for differences in RNA turnover
between recombinant NS5B and native HCV replicase.
Heparin is a competitive inhibitor of nucleic acid binding
and can function as a polymerase-trapping agent binding to
Fig. 3. Differential sensitivity of HCV replicase and NS5B to the inhibition
by heparin. (A) Replicase is resistant to heparin inhibition. Replicase
activity was determined in the absence () or presence of heparin at the
indicated concentrations. RNA product in the presence of heparin was
expressed as a percentage of the RNA product synthesized in the absence of
heparin and plotted. (B) Inhibition of recombinant NS5B by heparin.
Table 1
Inhibition of HCV replicase and recombinant NS5B RNA synthesis activity




3V-dCTP Compound 1 Compound 2 Compound 3
Replicase 0.31 F 0.18 N100 N100 N100
NS5b570 0.33 0.05 F 0.01 0.1 F 0.04 0.29 F 0.04
a Values represent means and standard deviations of IC50 values
determined from at least three independent experiments.
Rapid Communication 11and inhibiting free polymerase molecules, whereas produc-
tive polymerase–template complexes are resistant to inhib-
ition by heparin (Bambara et al., 1995; Tomei et al., 2000).
The replicase complex was preincubated with heparin for 10
min before the addition of assay buffer and NTP mixture to
allow replicase–heparin equilibration prior to initiation of
RNA synthesis. Fig. 3A shows full-length HCV replicon
RNA synthesis by CRC in the presence of heparin up to 1
mg/ml. The RdRp activity of the HCV replicase was
completely resistant to inhibition by heparin under these
conditions, consistent with a highly stable polymerase–
template RNA interaction in the CRC. In contrast, the RNA
synthesis activity of the recombinant NS5B protein was
sensitive to inhibition by heparin and completely inhibited
at heparin concentrations above 100 Ag/ml (Fig. 3B). These
results suggest that the native HCV replicase exists as a
stable and productive polymerase–RNA complex. Heparin
resistance of the replicase also indicates that the replicase
undergoes limited template RNA turnover under the assay
conditions, generating multiple copies of product from each
template. Alternatively, the RNA product generated by the
replicase may represent a single round of RNA replication
from the elongation of replication intermediates present at
the time of CRC preparation. Several lines of evidence
support the first hypothesis. Labeled RNA product gener-
ated by CRC increased linearly with time up to 180 min,
which is much longer than the estimated time requirement
for a single round of full-length replicon RNA synthesis
based on the previously reported elongation rate of 700
nucleotides per minute of the HCV polymerase in vitro
(Tomei et al., 2000). Full-length RNA product was
detectable very early in the replicase reaction and increased
in intensity linearly with time, consistent with the contin-
uous synthesis of new full-length copies (Fig. 1D). Studies
on the replication rates of other viruses from the Flavivir-
idae family, Kunjin and Dengue virus, showed that the cycle
of viral RNA synthesis to complete one full-length strand
was about 15 min (Chu and Westaway, 1985), consistent
with the detection of full-length transcripts generated by
HCV replicase at early reaction times. A recent study on the
replicase complex of bovine viral diarrhea virus showed that
the BVDV replicase retained a large proportion of RNA
synthesis activity even in the presence of 2 mg/ml of heparin
(Tomassini et al., 2003). Therefore, stable protein–template
RNA interaction may be a conserved feature of native,membrane-associated replicase complexes among viruses of
the Flaviviridae family. These results are different from
those described by Hardy et al. (2003), which showed high
heparin sensitivity of the HCV replicase purified from
replicon cells. The reason for the loss of heparin resistance
in that membrane preparation is unclear, but may be related
to slightly different cell fractionation protocols leading to
the loss of a stabilizing cofactor.
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properties of three classes of non-nucleoside compounds
The more stable interaction of polymerase with RNA
template in the replicase complex as compared to recombi-
nant NS5B may be related to the resistance of the replicase
to inhibition by non-nucleoside compounds. In order to
determine whether stable interaction with RNA template
was sufficient to generate resistance to inhibition by non-
nucleoside inhibitors and heparin, recombinant NS5B was
preincubated with RNA templates before assessment of
inhibitor potencies. NS5B was preincubated with the
heteropolymeric RNA template for a period up to 4 h
before the addition of heparin or each of the three non-
nucleoside compounds (Fig. 4). NS5B was inhibited to
more than 90% completion under these conditions, when
heparin or non-nucleoside inhibitors were added together
with template RNA (Fig. 4, time 0). As compared to the
activity in the absence of inhibitors, the RdRp activity of
NS5B became increasingly resistant to inhibition by
heparin, when NS5B was prebound to template RNA
before the addition of heparin and initiation of RNA
synthesis (Fig. 4, left panel). Acquiring resistance to heparin
by RNA binding was a slow process, reaching maximal
effect at about 2 h of preincubation of NS5B with HCV
cIRES RNA, suggesting a slow process of stable RNA
complex formation, possibly related to an RNA-induced
protein conformational change. Similar to the results
obtained with heparin, the RNA synthesis activity of
NS5B became largely resistant to inhibition by different
structural classes of non-nucleoside compounds after NS5B
preincubation with HCV cIRES RNA (Fig. 4, middle and
right panels). As observed with heparin, acquiring non-
nucleoside resistance by RNA binding was a slow process,
reaching plateau levels after 2 h of enzyme–template
preincubation. Similar results were obtained in experiments
performed with up to 1 mM compound concentration (data
not shown). In contrast, sensitivity of NS5B to inhibition byFig. 4. Effect of RNA template preincubation on the extent of inhibition of NS5B
preincubated for the indicated time periods before the addition of 1 mg/ml heparin
and 10 AM compound 3 (z). Residual activity in the presence of inhibitor was
inhibitor at each preincubation time point.3V-deoxy-CTP was not affected by NS5B–RNA complex
formation (Fig. 4, left panel).Discussion
The relative potencies of nucleotide and non-nucleoside
inhibitors of HCV RdRp were compared using native HCV
replicase and recombinant HCV polymerase, NS5B. As
described here, the native HCV replicase showed similar
sensitivity to inhibition by 3V-deoxy-CTP as compared to
NS5B under similar buffer and substrate incubation
conditions. These results suggest that the interaction of
NS5B with NTP substrates and NTP analogs is similar in
the isolated NS5B protein and the membrane associated
replicase complex. Consistent with our finding, triphos-
phates of 2V-modified nucleoside analogs also inhibited the
HCV replicase and the recombinant NS5B with comparable
potency (Migliaccio et al., 2003). Many non-nucleoside
inhibitors are allosteric inhibitors with binding sites distant
from the active site of the RdRp. The potency of this class of
inhibitors may depend on binding site accessibility and the
conformation of the polymerase. Here, none of the tested
representative compounds from three different structural
classes measurably inhibited RNA synthesis by HCV
replicase even at concentrations more than 1000-fold higher
than the concentrations required for half-maximal inhibition
of recombinant NS5B (Table 1), although structural and
biochemical analyses suggest that these compounds bind to
different, non-overlapping binding sites on NS5B protein.
Possible explanations for the resistance of the replicase
activity to these non-nucleoside inhibitors include (1)
different NS5B protein conformation related to productive
interaction of NS5B with template RNA, (2) protein–protein
interaction between NS5B and other HCV nonstructural
proteins or host proteins occluding compound binding sites
on NS5B, (3) oligomerization of NS5B during formation of
the replicase complex as suggested by in vitro studies withpolymerase activity. Recombinant NS5B and cIRES RNA template were
(5), 10 AM 3V-dCTP (x), 10 AM compound 1 (n), 10 AM compound 2 (E),
expressed as a percentage of the RNA synthesis activity in the absence of
Rapid Communication 13HCV NS5B or polio virus polymerase (Lyle et al., 2002;
Wang et al., 2002). The results obtained in NS5B-RNA
preincubation studies support the first hypothesis. Recombi-
nant NS5B protein was protected from inhibition by non-
nucleoside as well as heparin after preincubation with
template RNA, suggesting that a stable protein–template
RNA complex formed during the preincubation period is
sufficient to confer the resistance. Similar results were
recently reported with related compounds from two different
classes of non-nucleoside inhibitors, benzimidazoles and
benzothiadiazines (Tomei et al., 2003, 2004). Interestingly,
HCV polymerase inhibition by compound 3 from the novel
class of thiophene-carboxylic acids, which bind to a thumb
region separate from the binding sites of benzimidazole and
benzothiadiazine compounds also followed a similar pattern
of inhibition as compared to benzimidazoles and benzothia-
diazines. Therefore, unexpectedly, compounds binding to
three distinct binding sites on NS5B appear to require the
opportunity to bind to NS5B prior to formation of a stable
protein–template RNA complex to achieve polymerase
inhibition. Additional factors may contribute to the high
level of replicase resistance to the non-nucleoside inhibitors.
The isolated NS5B protein did not achieve full protection
from inhibition, even after prolonged preincubation with
RNA. The plateau residual activity reached maximal levels
of 50–75% after 2–4 h for all three non-nucleosides and
heparin, whereas a residual fraction of 25–50% of protein
remained apparently sensitive to inhibition. The complete
resistance of the native replicase complex as compared to
the partial resistance of the protein–RNA complex formed in
vitro could be related to an increased stability of the
polymerase–template complex in the replicase or to the fact
that reinitiation of the next round of RNA synthesis is more
efficient in replicase complex. Whether increased stability
of the protein–RNA complex in the replicase may be
conferred by the presence of additional protein–protein or
protein–RNA interactions in the multiprotein complex or by
the functional oligomerization of NS5B in the replicase
complex awaits further studies on the HCV replicase
assembly process.
The study described here established that the native HCV
replicase complex represents a stable and productive
protein–RNA complex with replicative RNA synthesis
activity. Allosteric inhibitors of NS5B may therefore
function via a common mechanism antagonistically with
the formation of a productive protein–template RNA
complex, despite binding to distinct, non-overlapping bind-
ing sites on NS5B. The previously observed inhibitory
effect of these allosteric compounds on HCV replication cell
culture therefore most likely results from the inhibition of
the formation of new replicase complexes. Discovery of
compounds, which could also interfere with the chemical
step of NMP incorporation or with NTP substrate binding to
NS5B may therefore further increase their overall impact on
HCV replication and the inhibitory potency of future non-
nucleoside inhibitors.Materials and methods
Compounds
Non-nucleoside inhibitors were synthesized at Roche
Palo Alto according to published procedures. 3V-deoxy-CTP
was purchased from TriLink Biotechnologies (#N-3003).
Preparation of cytoplasmic membrane fraction
Cytoplasmic membrane fractions were prepared from
Huh7 cells or a Huh7 derived cell line containing an
autonomously replicating HCV subgenomic replicon. Cell
rupture and cytoplasmic membrane fraction isolation were
performed as previously described (Takeda et al., 1986).
The isolated membrane fraction was stored in a buffer
containing 10 mM HEPES, pH 7.5, 10 mM NaCl, 1 mM
DTT, and 15% glycerol at 5  105 cell equivalent/Al at
80 8C until assay.
Protein expression and purification
E. coli strain M15 was used for the expression of HCV
NS5B570-BK, which contained an N-terminal histidine tag
and a 21 amino acid deletion at the C-terminus. The
construct containing the coding sequence of HCV BK strain
amino acid residues 2421–2999 (GenBank accession
number M58335) downstream of a Taq promoter expression
cassette was kindly provided by Hilary Overton, Roche
Discovery Welwyn. NS5B570-BK was purified sequentially
through Ni-NTA superflow, SP-Sepharose, and Superdex 75
columns. Eluted fractions were checked by SDS-PAGE and
homogeneous fractions containing NS5B570-BK were
pooled. Protein concentration was determined using Pierce
Coomassie Protein reagent.
In vitro replicase assay
The standard replicase assay reactions contained 10 Al
cytoplasmic membrane fraction, 50 mM HEPES, pH 7.5,
10 mM KCl, 10 mM DTT, 5 mM MgCl2, 20 Ag/ml
actinomycin D, 1 mM ATP, GTP, and UTP, 30 ACi
[a-33P]-CTP (3000 Ci/mmol, 10 mCi/ml), 1 U/Al SUPER-
ase.In (Ambion), 10 mM creatine phosphate, and 200 Ag/
ml creatine phosphokinase in a final volume of 25 Al. The
reaction mixtures were incubated at 30 8C for 120 min and
stopped by the addition of 50 mM EDTA and 0.5% SDS.
The RNA products were recovered by phenol–chloroform
extraction and ethanol precipitation following removal of
proteins by proteinase K digestion. The RNA products
were denatured in glyoxal sample loading buffer and
resolved in 1% agarose-Sodium phosphate gel. Autoradio-
graphic analysis of the RNA products was performed with
phosphoimager and ImageQuant software (Amersham
Biosciences). RNA synthesis activity in the presence
of inhibitor compounds was expressed as a percentage
Rapid Communication14of the RNA synthesis activity in the absence of inhibitor
compounds.
HCV polymerase assay
The 377-nucleotide-long cIRES RNA template, which
was derived from the complementary strand of the IRES
region of the HCV genome was generated by T7 RNA
polymerase mediated transcription using the MEGAscript
T7 Kit (Ambion). Enzymatic reaction mixtures containing
10 Ag/ml cIRES RNA template, 200 nM NS5B570-BK
enzyme, 2.1 ACi of tritiated UTP (42 Ci/mmol), 1 AM ATP,
CTP, and GTP, 1 TMD buffer (40 mM Tris–HCl pH 8.0, 4
mM DTT, and 4 mM MgCl2), 2.5 mM NaCl, with or
without inhibitors in a total volume of 50 Al were incubated
for 2 h at 30 8C. Reactions were stopped by the addition of
10% (v/v) trichloroacetic acid. The enzymatic activity of
NS5B570 BK was measured as incorporation of radio-
labeled nucleotide monophosphates into acid insoluble
RNA products. NS5B-RNA preincubation assay was based
on the HCV polymerase assay described above with the
following modifications. Mixture A (25 Al per reaction)
contained 20 Ag/ml cIRES RNA template, 400 nM
NS5B570-BK enzyme, and 1 TMD buffer. Mixture B
(25 Al per reaction) contained 4.2 ACi of tritiated UTP (42
Ci/mmol), 2 AM ATP, CTP, and GTP, 20 AM compound or 2
Ag/Al heparin, and 1 TMD buffer. Mixtures A were
incubated at room temperature for up to 4 h before the
addition of mixture B to start the reaction. The percent
relative activity was plotted as a function of preincubation
time.Acknowledgments
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